HIGHLIGHTS
- who: Giancarlo Castaman and colleagues from the Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy have published the Article: Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience, in the Journal: (JOURNAL)
- what: Emicizumab is designed for long-term prophylaxis in patients with severe hemophilia A with and without This approach provides constant protection with significant reduction in bleeding rate and improved quality of life. The authors report the experience in management of 75 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.